



AMENDMENT

In the Claims

The following listing reflects the currently pending claims. No amendments are made herein.

1-40 (Canceled)

41. (Previously presented) A fusion protein comprising an immunogenic polypeptide, wherein the immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8).

42. (Previously presented) The fusion protein of claim 41 linked to a suitable carrier.

43. (Previously presented) The fusion protein of claim 42 linked to a disulfide/amide-forming agent.

44. (Previously presented) The fusion protein of claim 42 linked to a thio-ether-forming agent.

45-51. (Canceled)

52. (Previously presented) An immunogenic composition comprising a pharmaceutically acceptable carrier and the fusion protein of claim 41.

53. (Cancelled)

54. (Canceled)

55. (Previously presented) The fusion protein of claim 42, wherein the carrier is diphtheria toxoid.

56. (Previously presented) The immunogenic composition of claim 52, wherein the carrier is diphtheria toxoid.

57. (Canceled)